The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Table 2 Clinical improvement as assessed by ACR criteria

Assessor (time point)	Response	ACZ885				Placebo (n = 15)	P value (10 mg/kg versus placebo)
		0.3 mg/kg (n = 6)	1.0 mg/kg (n = 6)	3.0 mg/kg (n = 6)	10 mg/kg (n = 19/20^a)
Blinded observer (day 43)	ACR20	1 (17%)	0 (0%)	4 (67%)	6 (32%)	1 (7%)	0.085
	ACR50	0 (0%)	0 (0%)	1 (17%)	3 (16%)	0 (0%)	0.162
	ACR70	0 (0%)	0 (0%)	0 (0%)	2 (11%)	0 (0%)	0.305
Investigator (any time within 6 weeks of treatment start)	ACR20	3 (50%)	2 (33%)	4 (67%)	10 (50%)	3 (20%)	0.070
	ACR50	0 (0%)	0 (0%)	2 (33%)	4 (20%)	0 (0%)	0.093
	ACR70	0 (0%)	0 (0%)	0 (0%)	3 (15%)	0 (0%)	0.174

Shown are the number and percentage of patients achieving 20%, 50%, or 70% improvement in terms of American College of Rheumatology (ACR) criteria (ACR20, ACR50 and ACR70, respectively) at day 43 as assessed by a blinded observer and at any time point within 6 weeks of treatment start as assessed by the investigator. ^aNote that for one patient in the 10 mg/kg treatment group, the ACR criteria assessment by a blinded observer was not conducted at day 43.

ISSN: 1478-6362